Autonomix medical, inc. initiates good laboratory practice (glp) study for sensing and rf ablation system

Glp study marks a key milestone in autonomix's path to achieve regulatory approvals company remains on track to submit investigational device exemption (“ide”), and if approved, commence u.s. clinical trials in 2026 to support a de novo fda application the woodlands, tx, sept. 29, 2025 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has commenced a good laboratory practice (glp) preclinical study required by the fda at cbset, a state-of-the-art pre-clinical translational research institute, for its sensing and rf ablation system as a treatment for pancreatic cancer pain.
AMIX Ratings Summary
AMIX Quant Ranking